🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It’s time to admit that genes are not the blueprint for life. Genetics alone cannot help us to understand and treat many of the diseases …such as …cancer. These conditions are physiological at their core nature.com/articles/d4158…

Translating p53-based therapies for cancer into the clinic ⁦Nature Reviews Cancer⁩ nature.com/articles/s4156…

This is a fairly comprehensive overview of what’s going on in the world of antibody-degrader conjugates. Still early days here. sciencedirect.com/science/articl…

Read our latest MD Anderson Cancer Center #research with Drs. Vivek Subbiah, MD David S. Hong MD, Meric-Bernstam, Piha-Paul et al on rechallenging the RAF pathway in solid tumors beyond melanoma from our Re-RAFFLE study published with Springer Nature in Molecular Cancer! rdcu.be/dCAzJ

In the RE-RAFFLE study led by our Dr. Blessie Nelson, patients who had multiple tumors with RAF alterations were rechallenged with a second RAF inhibitor. Learn about the findings of this study, and other new research at MD Anderson here: bit.ly/3VRAcd5 Blessie Elizabeth Nelson MBBS, DMRT

I am not a provider. Patients are not consumers.

B cell trajectories influence cancer outcomes | Science science.org/doi/10.1126/sc…

Accurate structure prediction of biomolecular interactions with AlphaFold 3 | Nature nature.com/articles/s4158…

TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer - PubMed. ⁦Razelle Kurzrock, MD⁩ pubmed.ncbi.nlm.nih.gov/38859842/

Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology | Nature Genetics nature.com/articles/s4158…

🚨 New Review JIPO Editors Blessie Elizabeth Nelson MBBS, DMRT We looked at: 🔎Impact of DCTs on Early Drug Development 🟢 Benefits | 🚧 Barriers 🗺️A Framework Proposal of implementation Aung Naing Camila Braganca Xavier Abdulrazzak Zarifa, MD Mohamed A Gouda

Review by Feustel et al. examines B7-H3 inhibitors in oncology clinical trials doi.org/10.36401/JIPO-… #cancer #clinicaltrial

Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine | JCO Precision Oncology ascopubs.org/doi/10.1200/PO…

The genomic landscape of 2,023 colorectal cancers | Nature nature.com/articles/s4158…

Protein isoform-centric therapeutics: expanding targets and increasing specificity tinyurl.com/2v5c3us8 Many genes encode multiple protein isoforms. This new review discusses targeting isoforms as a route to drugs with greater specificity and fewer adverse effects

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments | Journal for ImmunoTherapy of Cancer jitc.bmj.com/content/12/10/…

Happy to share our review on the complexity of the TME and perspectives on targeting approaches 🎯 Thank you for the strong team work JIPO Editors Aung Naing, MD Anderson Cancer Center Carlos Torrado & Princess Margaret Cancer Centre Diego Holanda Ana Veneziani Thais Megid | doi.org/10.36401/JIPO-…

Recent research article by Gouda et al. explores the treatment of malignant #melanoma through the drug combination of #selinexor and #pembrolizumab doi.org/10.36401/JIPO-… #immunotherapy #ICIs #JIPO Mohamed A Gouda Innovative Oncology Network

New #JITC article: Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors bit.ly/3ZgH0SF Aung Naing

Every year, the Njardarson's group (University of Arizona) compiles the top 200 brand drugs by sales. The 2024 list is now posted! For ADCs, 2023 vs 2024 ranks: Enhertu 65 ➡️ 51 Padcev >200 ➡️ 73 Kadcyla 67 ⬅️ 94 Trodelvy 162 ➡️146 Polivy 169 ➡️ 159 Total ~$13 billions!